The Evolution and Revolution in Cancer Treatment
We have seen a paradigm shift in cancer treatment towards more targeted therapies in all modalities, but particularly systemic treatments Cytotoxic drugs have given way to targeted small molecules and antibodies, and treatments can be selected using biomarkers to indicate the targets present in individual tumours. Immunotherapy is unlocking the potential of the body’s immune system to attack the cancer. Genomic analysis will become more important than histological subtype in selecting treatments and may be achieved by via liquid biopsies.
Ian Olver is a medical oncologist, bioethicist and researcher. He is currently Professor of Translational Cancer Research, and Director, University of South Australia Cancer Research Institute where he heads a psycho-oncology research team. He is immediate past President of the Multinational Association of Supportive Care in Cancer and Chaired the Australian Health Ethics Committee of the NHMRC for the past 6 years. He has published over 300 journal papers, 22 book chapters 4 books and edited 4 books. In 2008 he was awarded the Cancer Achievement Award by the Medical Oncology Group of Australia and in 2014 the Gold Medal of Cancer Council Australia for distinguished service in cancer. He was awarded Membership of the Order of Australia (AM) in 2011 “For service to medical oncology as a clinician, researcher, administrator and mentor, and to the community through leadership roles with cancer control organisations.